Preview Mode Links will not work in preview mode

Nov 7, 2023

What does the body of evidence say on Ozempic and its impact on diabetes and obesity? Plus: can you trade in your antidepressant for a jog, and Chris returns to the hot seat to diagnose a teenage boy who fell during a baseball game!

Block 1:

(2:22) Ozempic/Wegovy: GLP-1 receptor agonists; the difference between them; Mounjaro; Trulicity; diabetes biology; glucagon-like peptides 1 and 2; the problem with GLP-1; DPP4 inhibitors

Block 2:

(12:33) Ozempic/Wegovy: The venom of the Gila monster; how semaglutide became a blockbuster drug; weight loss; the numerous clinical trials; the impact on the stock prices of dialysis companies; downsides; the Internet craze

Block 3:

(27:03) Is running as beneficial for depression as medication?

Block 4:

(36:42) The case of the baseball player’s heart


* Jingle by Joseph Hackl

* Theme music: “Fall of the Ocean Queen“ by Joseph Hackl

* Assistant researcher: Aigul Zaripova


To contribute to The Body of Evidence, go to our Patreon page at:

To make a one-time donation to our show, you can now use PayPal!

Patrons get a bonus show on Patreon called “Digressions”! Check it out!



1) History of GLP-1 receptor agonists:

2) Liraglutide vs. exenatide:

3) Meta-analysis of GLP-1 receptor agonists:

4) A brief summary of the SUSTAIN studies, all 11 of them, which demonstrated the efficacy of semaglutide and its cardiovascular benefit:

5) A brief summary of the STEP trials, all 10 of them, which tested semaglutide as a weight loss medications even in non-diabetics:

6) Announcement that the FLOW trial is being stopped prematurely: &

7) GI side effects of GLP-1 receptor agonists:

8) Gid M-K’s Slate article:

9) Study on running to treat depression:

10) Details on the DEA-Quebec app to find an AED near you:

11) Government of Canada’s definition of a pesticide:


It’s Not Twitter, But It’ll Do:

1) Jonathan’s article on how natural health products and dietary supplements are regulated:

2) Jonathan’s article on fentanyl:

3) Chris’ article in Medscape about the COSMOS study:

4) Chris’ Gazette article on coated vs. uncoated aspirin: